# The Impact of Maternal Diabetes and Hypothyroidism on Signaling Pathway Activation and Gene Expression in Fetal Mesenchymal Stem Cells

**Authors:** Dominika Przywara, Wiktor Babiuch, Alicja Petniak, Bartosz Piszcz, Arkadiusz Krzyżanowski, Adrianna Kondracka, Janusz Kocki, Paulina Gil-Kulik

PMC · DOI: 10.3390/biomedicines14020436 · Biomedicines · 2026-02-14

## TL;DR

This study explores how maternal diabetes and hypothyroidism affect gene expression and signaling pathways in fetal mesenchymal stem cells.

## Contribution

The study identifies specific signaling pathways and gene expression changes in UC-MSCs influenced by maternal diabetes and hypothyroidism.

## Key findings

- Diabetes upregulated genes linked to WNT/PCP signaling and smooth muscle activity.
- Hypothyroidism increased expression of MMP1, MMP10, and GREM1, and affected extracellular matrix pathways.
- Both conditions altered gene expression in UC-MSCs, suggesting potential impacts on regenerative medicine applications.

## Abstract

Background: Mesenchymal stem cells (MSCs) exhibit a high capacity for differentiation, possess anti-inflammatory and proangiogenic properties, and stimulate the growth and proliferation of neighboring cells. MSCs are a promising tool in regenerative medicine. However, the molecular mechanisms underlying the properties of these cells are not yet fully understood. Gene expression in MSCs influences their characteristics and differentiation potential. Therefore, it is essential to investigate factors affecting gene expression as well as those activating signaling pathways, which will enable more effective and individualized applications of MSCs. In this study, we aimed to identify signaling pathways involved in gene expression in umbilical cord-derived MSCs (UC-MSCs) that may be altered by maternal diabetes and hypothyroidism during pregnancy. Methods: The research material consisted of UC-MSCs. Samples obtained from nine participants were analyzed. UC-MSCs were isolated and cultured, and RNA was extracted. The isolated RNA was used for microarray-based gene expression analysis. Subsequently, pathway enrichment analysis was performed to identify the signaling pathways involved. Results: In the diabetes group, 340 genes (0.71%) were upregulated, while 268 genes (0.56%) were downregulated compared with UC-MSCs from the control group. In the diabetes group, the most compact module was composed of proteins associated with WNT/planar cell polarity (WNT/PCP) signaling. The second module included genes related to smooth muscle activity. In the hypothyroidism group, an association was identified between the extracellular matrix organization pathways (GO:0030198) and the extracellular structure organization (GO:0043062) pathways. Moreover, in this group, increased expression of MMP1, MMP10, and GREM1 was observed. Conclusions: In summary, our study demonstrated the impact of diabetes and hypothyroidism on gene expression in UC-MSCs. We also observed the activation of distinct signaling pathways depending on the presence of these conditions. However, this work represents a preliminary screening, and the results should be validated by PCR in a larger cohort.

## Linked entities

- **Genes:** MMP1 (matrix metallopeptidase 1) [NCBI Gene 4312], MMP10 (matrix metallopeptidase 10) [NCBI Gene 4319], GREM1 (gremlin 1, DAN family BMP antagonist) [NCBI Gene 26585]
- **Diseases:** diabetes (MONDO:0005015), hypothyroidism (MONDO:0005420)

## Full-text entities

- **Genes:** VANGL2 (VANGL planar cell polarity protein 2) [NCBI Gene 57216] {aka LPP1, LTAP, STB1, STBM, STBM1}, DES (desmin) [NCBI Gene 1674] {aka CDCD3, CSM1, CSM2, LGMD1D, LGMD1E, LGMD2R}, GREM1 (gremlin 1, DAN family BMP antagonist) [NCBI Gene 26585] {aka C15DUPq, CKTSF1B1, CRAC1, CRCS4, DAND2, DRM}, CNN1 (calponin 1) [NCBI Gene 1264] {aka HEL-S-14, SMCC, Sm-Calp}, CELSR1 (cadherin EGF LAG seven-pass G-type receptor 1) [NCBI Gene 9620] {aka ADGRC1, CDHF9, FMI2, HFMI2, LMPHM9, ME2}, FMN2 (formin 2) [NCBI Gene 56776], DAAM2 (dishevelled associated activator of morphogenesis 2) [NCBI Gene 23500] {aka NPHS24, dJ90A20A.1}, TBX4 (T-box transcription factor 4) [NCBI Gene 9496] {aka ICPPS, PAPPAS, SPS}, TJP1 (tight junction protein 1) [NCBI Gene 7082] {aka ZO-1}, VANGL1 (VANGL planar cell polarity protein 1) [NCBI Gene 81839] {aka KITENIN, LPP2, STB2, STBM2}, PRICKLE1 (prickle planar cell polarity protein 1) [NCBI Gene 144165] {aka EPM1B, RILP}, MMP10 (matrix metallopeptidase 10) [NCBI Gene 4319] {aka SL-2, STMY2}, GUCY1B1 (guanylate cyclase 1 soluble subunit beta 1) [NCBI Gene 2983] {aka GC-S-beta-1, GC-SB3, GUC1B3, GUCB3, GUCSB3, GUCY1B3}, ACTR3 (actin related protein 3) [NCBI Gene 10096] {aka ARP3}, FZD3 (frizzled class receptor 3) [NCBI Gene 7976] {aka Fz-3}, ECE1 (endothelin converting enzyme 1) [NCBI Gene 1889] {aka ECE}, CDH7 (cadherin 7) [NCBI Gene 1005] {aka CDH7L1}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, MYH11 (myosin heavy chain 11) [NCBI Gene 4629] {aka AAT4, FAA4, SMHC, SMMHC, SMMS-1, VSCM2}, NDN (necdin, MAGE family member) [NCBI Gene 4692] {aka HsT16328, PWCR}, CDC42 (cell division cycle 42) [NCBI Gene 998] {aka CDC42Hs, G25K, TKS}, MMP1 (matrix metallopeptidase 1) [NCBI Gene 4312] {aka CLG}, PTGIS (prostaglandin I2 synthase) [NCBI Gene 5740] {aka CYP8, CYP8A1, PGIS, PTGI}, ID3 (inhibitor of DNA binding 3) [NCBI Gene 3399] {aka HEIR-1, bHLHb25}, MIR324 (microRNA 324) [NCBI Gene 442898] {aka MIRN324, hsa-mir-324, mir-324}, XYLT1 (xylosyltransferase 1) [NCBI Gene 64131] {aka DBQD2, PXYLT1, XT-I, XT1, XTI, XYLTI}, KIF15 (kinesin family member 15) [NCBI Gene 56992] {aka BRDCS2, HKLP2, KLP2, KNSL7, NY-BR-62}, SORBS1 (sorbin and SH3 domain containing 1) [NCBI Gene 10580] {aka CAP, FLAF2, R85FL, SH3D5, SH3P12, SORB1}, ACKR3 (atypical chemokine receptor 3) [NCBI Gene 57007] {aka CMKOR1, CXC-R7, CXCR-7, CXCR7, GPR159, RDC-1}, THY1 (Thy-1 cell surface antigen) [NCBI Gene 7070] {aka CD90, CDw90}, KCNE4 (potassium voltage-gated channel subfamily E regulatory subunit 4) [NCBI Gene 23704] {aka MIRP3}, KIF13B (kinesin family member 13B) [NCBI Gene 23303] {aka GAKIN}, PRCP (prolylcarboxypeptidase) [NCBI Gene 5547] {aka HUMPCP, PCP}, RHOA (ras homolog family member A) [NCBI Gene 387] {aka ARH12, ARHA, EDFAOB, RHO12, RHOH12}, TRIM32 (tripartite motif containing 32) [NCBI Gene 22954] {aka BBS11, HT2A, LGMD2H, LGMDR8, TATIP}, WBP1L (WW domain binding protein 1 like) [NCBI Gene 54838] {aka C10orf26, OPA1L, OPAL1}, NT5E (5'-nucleotidase ecto) [NCBI Gene 4907] {aka CALJA, CD73, E5NT, NT, NT5, NTE}, LMOD1 (leiomodin 1) [NCBI Gene 25802] {aka 1D, 64kD, D1, MMIHS3, SM-LMOD, SMLMOD}, PRICKLE2 (prickle planar cell polarity protein 2) [NCBI Gene 166336] {aka EPM5}, PLXNA4 (plexin A4) [NCBI Gene 91584] {aka FAYV2820, PLEXA4, PLXNA4A, PLXNA4B, PRO34003}, MSC (musculin) [NCBI Gene 9242] {aka ABF-1, ABF1, MYOR, bHLHa22}, PTPRT (protein tyrosine phosphatase receptor type T) [NCBI Gene 11122] {aka R-PTP-T, RPTP-rho, RPTPrho}, DVL3 (dishevelled segment polarity protein 3) [NCBI Gene 1857] {aka DRS3}, GHR (growth hormone receptor) [NCBI Gene 2690] {aka GHBP, GHIP}, APBA1 (amyloid beta precursor protein binding family A member 1) [NCBI Gene 320] {aka D9S411E, LIN10, MINT1, X11, X11A, X11ALPHA}, PID1 (phosphotyrosine interaction domain containing 1) [NCBI Gene 55022] {aka HMFN2073, NYGGF4, P-CLI1, PCLI1}
- **Diseases:** thyroid dysfunction (MESH:D013959), renal injury (MESH:D007674), pregnancy loss (MESH:D000022), pulmonary fibrosis (MESH:D011658), glucose intolerance (MESH:D018149), diabetic nephropathy (MESH:D003928), Maternal (MESH:D000079262), Hypothyroidism (MESH:D007037), hypertension (MESH:D006973), hypoglycemia (MESH:D007003), preterm birth (MESH:D047928), T4 deficiency (MESH:D005067), Endocrine disorders (MESH:D004700), chronic pancreatitis (MESH:D050500), UC (MESH:C536938), autoimmune conditions (MESH:D001327), GDM (MESH:D016640), jaundice (MESH:D007565), systemic diseases (MESH:D034721), inflammatory (MESH:D007249), metabolic and degenerative disorders (MESH:D019636), injury to (MESH:D014947), hyperglycemia (MESH:D006943), cancers (MESH:D009369), Diabetes (MESH:D003920)
- **Chemicals:** alcohol (MESH:D000438), T3 (MESH:D014284), glucose (MESH:D005947), levothyroxine (MESH:D013974)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** UC-MSCs — Homo sapiens (Human), Finite cell line (CVCL_B5ZH)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12938452/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12938452/full.md

## References

47 references — full list in the complete paper: https://tomesphere.com/paper/PMC12938452/full.md

---
Source: https://tomesphere.com/paper/PMC12938452